{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"58","value":"1013"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"C1D7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57","value":"991.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"C1D15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Maximum plasma concentration of glasdegib dosed in combination with azacitidine (C1D7) and when dosed alone (C1D15) in the Lead-in Cohort was estimated using non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration analysis set included all participants who received treatment and had at least 1 value of analyte concentration of glasdegib or azacitidine available. Number of participants analyzed = number of participants evaluable for this OM. Number analyzed = number of participants with evaluable results at the specific timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 0.25, 1, 4, 6, 24 hours post-dose on Cycle 1 Day 7 and Cycle 1 Day 15","title":"Maximum Plasma Concentration (Cmax) of Glasdegib Dosed in Combination With Azacitidine (C1D7) and When Dosed Alone (C1D15) in the Lead-in Cohort","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}